Nuo Therapeutics, Inc.
AURX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,365 | $609 | $112 | $0 |
| % Growth | 124.3% | 442.1% | – | – |
| Cost of Goods Sold | $303 | $126 | $19 | $0 |
| Gross Profit | $1,062 | $482 | $93 | $0 |
| % Margin | 77.8% | 79.3% | 82.9% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $91 |
| SG&A Expenses | $3,520 | $3,651 | $3,414 | $91 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $5 | $0 |
| Operating Expenses | $3,520 | $3,651 | $3,414 | $91 |
| Operating Income | -$2,458 | -$3,168 | -$3,321 | -$91 |
| % Margin | -180% | -520.6% | -2,958.2% | – |
| Other Income/Exp. Net | $134 | -$3 | $149 | $0 |
| Pre-Tax Income | -$2,324 | -$3,171 | -$3,172 | -$91 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,324 | -$3,171 | -$3,025 | -$91 |
| % Margin | -170.2% | -521.2% | -2,695.1% | – |
| EPS | -0.051 | -0.075 | -0.076 | -0.003 |
| % Growth | 32.1% | 0.3% | -2,420% | – |
| EPS Diluted | -0.051 | -0.075 | -0.076 | -0.003 |
| Weighted Avg Shares Out | 45,424 | 42,078 | 40,001 | 30,296 |
| Weighted Avg Shares Out Dil | 45,424 | 42,078 | 40,001 | 30,296 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $3 | $2 | $0 |
| Depreciation & Amortization | $96 | $105 | $74 | $91 |
| EBITDA | -$2,362 | -$3,063 | -$3,096 | $0 |
| % Margin | -173% | -503.4% | -2,757.7% | – |